Mineralys Therapeutics (MLYS) shares were up premarket Monday after the company said lorundrostat met primary endpoints in both the phase 3 Launch-HTN and phase 2 Advance-HTN trials in patients with uncontrolled hypertension or resistant hypertension.
The company said the phase 3 study showed a statistically significant drop in systolic blood pressure compared with placebo by week six until week 12.
In the phase 2 trial, lorundrostat also led to a statistically significant placebo-adjusted drop of 7.9 mmHg in systolic pressure at week 12, Mineralys said.
Mineralys said the treatment was generally well tolerated in both studies, with low rates of serious side effects and elevated potassium levels. The company said it plans to present more data at a medical conference later this month and continue collecting longer-term results in an extension study.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。